Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates

Xiaolong He1,2, Jie Gao1,2, Liang Peng3

  • 1Department of Infectious Disease, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of Sun Yat-sen University, Jiangmen, Guangdong, China.

Gut
|December 14, 2020
PubMed
Abstract

Insights

Gut bacteria possess O-linked N-acetylglucosaminidase (OGA) enzymes that reduce gut inflammation by modifying host proteins. These bacterial OGA genes are abundant in healthy guts but decreased in ulcerative colitis.

Area of Science:

  • Microbiology
  • Molecular Biology
  • Immunology

Background:

  • O-linked N-acetylglucosaminylation (O-GlcNAcylation) is a critical post-translational modification regulating gut inflammation.
  • Gut microbiota contain enzymes involved in O-GlcNAcylation, but their roles remain largely uncharacterized.

Purpose of the Study:

  • To investigate the characteristics, abundance, and function of bacterial enzymes involved in O-GlcNAcylation, specifically O-linked N-acetylglucosaminidases (OGAs) and O-GlcNAc transferases (OGTs).
  • To determine the impact of bacterial OGAs on host cell protein modification and gut inflammatory responses.

Main Methods:

  • Taxonomic distribution and structural analysis of bacterial OGAs and OGTs.
  • Metagenomic analysis of OGA gene abundance in healthy and diseased human gut samples.
  • In vitro and in vivo experiments to assess the enzymatic activity and anti-inflammatory effects of bacterial OGAs.

Main Results:

  • Bacterial OGAs, not OGTs, are enriched in major gut phyla (Bacteroidetes, Firmicutes) and often secreted with conserved catalytic domains.
  • Bacterial OGA genes are abundant in healthy guts but significantly reduced in ulcerative colitis patients.
  • Bacterial OGAs hydrolyze host O-GlcNAcylated proteins, including NF-κB-p65, and protect against chemically induced colonic inflammation in mice.

Conclusions:

  • Gut microbiota-derived OGAs possess enzymatic activity that influences intestinal physiology.
  • Bacterial OGAs represent a potential therapeutic target for managing colonic inflammation.